Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
---|
05/01/2013 | CN102180879B Polycrystalline type alpha acetic acid solvate of hypnotic |
05/01/2013 | CN102174626B Method for preparing corn peptide |
05/01/2013 | CN102058535B Novel folate receptor targeted liposome |
05/01/2013 | CN102036976B Modulators of dopamine neurotransmission |
05/01/2013 | CN102026643B The use and method of the compound of fasudil and the pharmaceutical composition thereof |
05/01/2013 | CN101954107B Solid aromatic sleep aid and preparation method thereof |
05/01/2013 | CN101821246B Tetrazole-substituted aryl amide derivatives and uses thereof |
05/01/2013 | CN101810586B L-dopa methyl ester sustained-release microsphere composite and preparation method thereof |
05/01/2013 | CN101679270B Dihydroquinone and dihydronaphthridine inhibitors of JNK |
05/01/2013 | CN101664408B Stabilization of hypoxia inducible factor (HIF) alpha |
05/01/2013 | CN101558057B 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders |
05/01/2013 | CN101558038B Curcumin derivative |
05/01/2013 | CN101554397B Applications of eucommia ulmoide total alkaloid |
05/01/2013 | CN101495469B N-(aminoheteroaryl)-1H-indole-2-carboxamide derivatives as antagonist of TRPV1 or VR1 receptor, preparation thereof and therapeutic use thereof |
05/01/2013 | CN101448831B Imidazo [1, 2-b] pyridazines, their processes of preparation and their use as GABA receptor ligands |
05/01/2013 | CN101416976B External medicine composition preparation with anti-inflammation detumescence pain-easing function |
05/01/2013 | CN101300005B N-2 adamantanyl-2-phenoxy-acetamide derivatives as 11-beta hydroxysteroid dehydrogenase inhibitors |
05/01/2013 | CN101282721B Composition for relieving subjective symptoms of fatigue |
04/30/2013 | USRE44186 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
04/30/2013 | US8431613 Memory fixation accelerator |
04/30/2013 | US8431606 Medicament for treating schizophrenia comprising cilostazol |
04/30/2013 | US8431589 2,4-diaminopyrimidine derivatives |
04/30/2013 | US8431565 Substituted imidazoheterocycles |
04/30/2013 | US8431159 Solid pharmaceutical dispersions with enhanced bioavailability |
04/30/2013 | US8431121 Specifically targeted catalytic antagonists and uses thereof |
04/30/2013 | CA2696948C 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones |
04/30/2013 | CA2589289C Use of (-)-1-(benzofuran-2-yl)-2-propylaminopentane to treat substance dependence |
04/30/2013 | CA2584567C Pyrazolo (1,5-alpha) pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists |
04/30/2013 | CA2579756C Modulators of central nervous system neurotransmitters |
04/30/2013 | CA2571487C Pyrrazolo-pyrimidine derivatives |
04/30/2013 | CA2570606C Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders |
04/25/2013 | WO2013059791A2 Methods and compositions for promoting axon regeneration and nerve function |
04/25/2013 | WO2013059786A1 Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease |
04/25/2013 | WO2013059449A1 Treatment of withdrawal symptoms to aid in nicotine use cessation with passiflora incarnata |
04/25/2013 | WO2013059222A1 2-pyridyloxy-4-nitrile orexin receptor antagonists |
04/25/2013 | WO2013059119A1 Glucosylceramide synthase inhibitors and therapeutic methods using the same |
04/25/2013 | WO2013058681A2 Substituted phenoxyacetic acids and esters and amides thereof, comprising a 2,6-dioxo-2,3,6,7-tetrahydro-1н-purine-8-yl fragment and constituting а2a adenosine receptor antagonists, and the use thereof |
04/25/2013 | WO2013058605A1 Pharmaceutical composition comprising fluoxetine as an active ingredient, for preventing or treating blood-brain barrier disorders |
04/25/2013 | WO2013058303A1 Medicinal composition |
04/25/2013 | WO2013058258A1 Bicyclic heterocyclic compound |
04/25/2013 | WO2013057944A1 Novel spiroindoline compound, and medicinal agent comprising same |
04/25/2013 | WO2013057554A2 Therapeutic combinations of netupitant and palonosetron |
04/25/2013 | WO2013057322A1 (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
04/25/2013 | WO2013057222A2 Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones |
04/25/2013 | WO2013057124A1 Solid forms of 1,l-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone |
04/25/2013 | WO2013056326A1 Controlled release pharmaceutical composition containing naltrexone and topiramate |
04/25/2013 | WO2013030218A4 Selective and reversible inhibitors of ubiquitin specific protease 7 |
04/25/2013 | WO2013027986A3 Method of screening for chaperonin modulator |
04/25/2013 | WO2013025474A9 Compositions and methods for regulating neutrophil movement and neutrophil numbers in a body region |
04/25/2013 | WO2013025442A3 Concentrated felbamate formulations for parenteral administration |
04/25/2013 | WO2013009981A9 Treating neurological disease or injury with a dynamin-related protein 1 (drp1) encoding nucleic acid |
04/25/2013 | WO2012122340A8 Soluble guanylate cyclase activators |
04/25/2013 | WO2012010974A8 Combination pharmaceutical compositions and method of treatment of vertigo, kinetosis and vegetative-vascular dystonia |
04/25/2013 | US20130102898 Liposome including elastin-like polypeptides and use thereof |
04/25/2013 | US20130102690 Collagen-polysaccharide materials mimicking blood vessels, tissues and bones for medical, pharmaceutical and orthopedic applications, and processes for producing the same |
04/25/2013 | US20130102619 2-pyridyloxy-4-nitrile orexin receptor antagonists |
04/25/2013 | US20130102616 Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride |
04/25/2013 | US20130102612 Topical dermal brimonidine compositions |
04/25/2013 | US20130102584 Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
04/25/2013 | US20130102553 Therapeutic Strategies For Prevention And Treatment Of Alzheimer's Disease |
04/25/2013 | US20130102544 Disease-Associated Proteins |
04/25/2013 | US20130102073 Methods for making and using reprogrammed human somatic cell nuclei and autologous and isogenic human stem cells |
04/25/2013 | US20130101667 Cyclohexylamines |
04/25/2013 | US20130101627 Composition with extracts from olive leaf, yarrow and rosemary for treating human diseases and conditions |
04/25/2013 | US20130101610 Therapeutic Uses of CD137 in Treating Autoimmune Disease |
04/25/2013 | US20130101601 Antibodies directed against nerve growth factor (ngf) |
04/25/2013 | US20130101595 Antibodies that bind il-18 and methods of inhibiting il-18 activity |
04/25/2013 | US20130101580 Compositions and methods for prolonging lifespan |
04/25/2013 | US20130101577 Extended Soluble PH20 Polypeptides and uses thereof |
04/25/2013 | US20130101565 Use of carbonic anhydrase ii for producing a drug |
04/25/2013 | US20130101557 Recombinant Adenovirus Having Anti-Angiogenesis Activity |
04/25/2013 | US20130101510 Methods of treating parkinson's disease using viral vectors |
04/25/2013 | US20130098377 Excipients for nicotine-containing therapeutic compositions |
04/25/2013 | US20130098357 Cerivastatin to treat pulmonary disorders |
04/25/2013 | DE112011102362T5 Pharmazeutische Kombinationszusammensetzung und Verfahren zur Behandlung von Erkrankungen oder Zuständen, die mit neurodegenerativen Erkrankungen in Verbindung stehen A pharmaceutical combination composition and methods for treating diseases or conditions associated with neurodegenerative diseases in connection |
04/25/2013 | CA2852618A1 Pharmaceutical composition |
04/25/2013 | CA2852607A1 Use of avermectin derivative for increasing bioavailability and efficacy of macrocylic lactones |
04/25/2013 | CA2852469A1 Codon signature for neuromyelitis optica |
04/25/2013 | CA2852425A1 2-pyridyloxy-4-nitrile orexin receptor antagonists |
04/25/2013 | CA2852268A1 Biomarkers predictive of responsiveness to alpha 7 nicotinic acetylcholine receptor activator treatment |
04/25/2013 | CA2851589A1 Bicyclic heterocyclic compound |
04/25/2013 | CA2850441A1 Solid forms of 1,l-dioxo-4-thiomorpholinyl)-[6-[[3(4-fluorophenyl)-5-methyl-4-isoxazolyl]methoxy]-3-pyridinyl]-methanone |
04/25/2013 | CA2849564A1 (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors |
04/24/2013 | EP2583963A1 Proline analogs as ligands for cannabinoid receptors for the treatment of pain |
04/24/2013 | EP2583692A1 Inhibitor of expression of dominant allele |
04/24/2013 | EP2583687A1 Use of botulinum toxin for treating hyperhydrosis |
04/24/2013 | EP2582832A1 Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders |
04/24/2013 | EP2582705A1 Anellated pyridine compounds as dual modulators of the 5-ht2a and d3 receptors |
04/24/2013 | EP2582704A2 Asenapine maleate |
04/24/2013 | EP2582676A1 Tetrahydroquinoline amide m1 receptor positive allosteric modulators |
04/24/2013 | EP2582666A2 Aryl substituted indoles and their use as blockers of sodium channels |
04/24/2013 | EP2582393A1 Dose selection of adjuvanted synthetic nanocarriers |
04/24/2013 | EP2582375A2 Compositions and methods for the treatment of addiction, psychiatric disorders, and neurodegenerative disease |
04/24/2013 | EP2582374A2 Methods for treating neurological conditions |
04/24/2013 | EP2582368A1 Acetyl-carnitine for use in a method for increasing neurogenesis in neural tissue |
04/24/2013 | EP2343275B1 Crystalline form of the optical enantiomers of modafinil |
04/24/2013 | CN1935141B Use of descarboethoxyloratadine or its pharmaceutical salts in preparing medicine for treating urticaria |
04/24/2013 | CN1922320B Antisense compounds targeted to connexins and methods of use thereof |
04/24/2013 | CN1726915B Nasal cavity drug delivery system and combination of naloxone hydrochloride and preparation method |
04/24/2013 | CN1653050B Opioid and opioid-like compounds and uses thereof |